Skip to main content
Clinical Trials/NL-OMON50212
NL-OMON50212
Completed
Not Applicable

Efficacy of [18F]-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) in Evaluation of Cytological indeterminate Thyroid nodules prior to Surgery: a multicentre cost-effectiveness study. - EfFECTS

Radiologie & Nucleaire Geneeskunde0 sites132 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
thyroid lump
Sponsor
Radiologie & Nucleaire Geneeskunde
Enrollment
132
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Radiologie & Nucleaire Geneeskunde

Eligibility Criteria

Inclusion Criteria

  • Summary of main criteria from protocol v2\.0 paragraph 4\.2:
  • In order to be eligible for participation, a subject must meet ALL of the
  • following criteria:
  • 1\. solitary thyroid nodule or dominant thyroid nodulus within multinodular
  • disease, cytologically indeterminate (Bethesda category III or IV)
  • 2\. Scheduled for surgical excision (preferably) within 2 months of the
  • inclusion date;
  • 3\. Age \* 18 years;
  • 4\. Euthyroid state with a serum TSH or a free T4 level within the institutional
  • upper and lower limits of normal, measured within 2 months of registration. In

Exclusion Criteria

  • Summary of main criteria from protocol v2\.0 paragraph 4\.3:
  • A subject who meets ANY of the following criteria will be excluded from
  • participation:
  • 1\. high prior probability of malignancy (e.g. proven malignant cytology:
  • Bethesda cat. V or VI, malignant lymphadenopathy, PET positive thyroid
  • incidentaloma, genetic predisposition of thyroid carcinoma, prior radiotherapy
  • to the neck, etc.)
  • 2\. proven benign disease or insufficient material for diagnosis (Bethesda cat.
  • 3\. performance of additional non\-routine diagnostic tests affecting patient
  • management (e.g. mutation analysis on cytology)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 2
The utility of 18F-fluro-deoxy-glucose (FDG) and 11C-choline (C) positron emission tomography (PET scan) for radiotheraupetic management of high risk prostate cancer patientsProstate cancerCancer - Prostate
ACTRN12609000108213Austin Health30
Completed
Not Applicable
The usefulness of fluorodeoxyglucose-positron emission tomography as a preoperative diagnostic tool for thymic epithelial tumorsThymic epithelial tumors
JPRN-UMIN000040365Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences51
Recruiting
Not Applicable
Prognostic Siginificance of (18)F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Limited Stage Small Cell Lung Cancerimited Stage Small Cell Lung Cancer
JPRN-UMIN000004385ung Oncology Group in Kyushu, Japan (LOGIK)38
Completed
Not Applicable
Assessing the efficacy of FDG-PET(18F-fluorodeoxy glucose positron emission tomography) in the early detection of RCC (Renal cell carcinoma) in patients with ESRD(End stage renal disease)Renal cell carcinoma related with end stage renal disease
JPRN-UMIN000009336Gunma University Hospital department of nuclear medecine150
Completed
Not Applicable
A study of usefulness of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the initial staging and assessment of response to treatment in locally advanced breast cancerHealth Condition 1: null- patients with locally advanced breast cancer
CTRI/2018/04/013455Sri Venkateswara Institute of Medical Sciences